Paper29972759
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Abou-Alfa GK and 21 others. N Engl J Med, 2018. Cited by 1,923 papers, by iCite.
Cite this record
ConductScience Library. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. Papers, record 29972759. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29972759
- Disease
- hepatocellular carcinoma478 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anilides | Major topic |
| Antineoplastic Agents | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Pyridines | Major topic |
| Receptor Protein-Tyrosine Kinases | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Disease-Free Survival | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed | NIH RePORTER |
| P30 CA014089 | NCI NIH HHS | United States | P30CA014089 | PubMed | NIH RePORTER |
Trials6
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01908426 | Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC | Results | ClinicalTrials.gov | |
| NCT05425004 | Cabozantinib for Patients With Recurrent or Progressive Meningioma | Background | ClinicalTrials.gov | |
| NCT05831969 | Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC | Background | ClinicalTrials.gov | |
| NCT06007846 | A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer | Background | ClinicalTrials.gov | |
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab | Background | ClinicalTrials.gov |
Comments and corrections3
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 30285325 | Cabozantinib in Hepatocellular Carcinoma. | https://conductscience.org/library/papers/30285325 | PubMed |
| Comment in | 30881965 | Cabozantinib and the moving field of systemic treatments in advanced hepatocellular carcinoma. | https://conductscience.org/library/papers/30881965 | PubMed |
| Comment in | 31098366 | Cabozantinib for advanced hepatocellular carcinoma. | https://conductscience.org/library/papers/31098366 | PubMed |
References29
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19095497 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19095497 | PubMed |
| 2 | 7973215 | Interim analysis: the alpha spending function approach. | Stat Med | 1994 | https://conductscience.org/library/papers/7973215 | PubMed |
| 3 | 26959385 | Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. | Cancer | 2016 | https://conductscience.org/library/papers/26959385 | PubMed |
| 4 | 27834845 | The Receptor Tyrosine Kinase AXL in Cancer Progression. | Cancers (Basel) | 2016 | https://conductscience.org/library/papers/27834845 | PubMed |
| 5 | 22270953 | Targeting MET in cancer: rationale and progress. | Nat Rev Cancer | 2012 | https://conductscience.org/library/papers/22270953 | PubMed |
| 6 | 21926191 | Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. | Mol Cancer Ther | 2011 | https://conductscience.org/library/papers/21926191 | PubMed |
| 7 | 25568918 | The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/25568918 | PubMed |
| 8 | 22424438 | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. | J Hepatol | 2012 | https://conductscience.org/library/papers/22424438 | PubMed |
| 9 | 26364599 | Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. | Oncogene | 2016 | https://conductscience.org/library/papers/26364599 | PubMed |
| 10 | 12726861 | Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. | Cancer Cell | 2003 | https://conductscience.org/library/papers/12726861 | PubMed |
| 11 | 24700742 | Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/24700742 | PubMed |
| 12 | 27279544 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27279544 | PubMed |
| 13 | 19406039 | NCCN clinical practice guidelines in oncology: hepatobiliary cancers. | J Natl Compr Canc Netw | 2009 | https://conductscience.org/library/papers/19406039 | PubMed |
| 14 | 28426123 | Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. | Ann Oncol | 2017 | https://conductscience.org/library/papers/28426123 | PubMed |
| 15 | 29625879 | Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29625879 | PubMed |
| 16 | 26790028 | Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells. | Cancer Sci | 2016 | https://conductscience.org/library/papers/26790028 | PubMed |
| 17 | 23980090 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23980090 | PubMed |
| 18 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 19 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 20 | 26406150 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406150 | PubMed |
Cited by1,398
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1,923 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964795 | Same organ, divergent immunity: T-cell exhaustion versus stromal exclusion in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. | Front Immunol | 2026 | https://conductscience.org/library/papers/42964795 | PubMed |
| 42953395 | 68Ga/177Lu-Labeled Seribantumab as the Theranostic Drugs in Treating HER3-Positive Hepatocellular Carcinoma. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42953395 | PubMed |
| 42930143 | β-Catenin Signaling in Hepatocellular Carcinoma: Mechanisms of Therapeutic Resistance and Emerging Therapeutic Strategies. | Curr Oncol | 2026 | https://conductscience.org/library/papers/42930143 | PubMed |
| 42927511 | Regorafenib induces ferroptosis in hepatocellular carcinoma via the EGFR-TNF/NF-κB signaling axis. | Apoptosis | 2026 | https://conductscience.org/library/papers/42927511 | PubMed |
| 42907488 | Inhibition of ACSS2 enhances cabozantinib sensitivity by blocking TFEB-induced autophagic flux in hepatocellular carcinoma. | Br J Cancer | 2026 | https://conductscience.org/library/papers/42907488 | PubMed |
| 42882770 | Re-Evaluating Multi-Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Combined Therapy in Colorectal Cancer: A Preclinical Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42882770 | PubMed |
| 42870868 | Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42870868 | PubMed |
| 42836499 | Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment. | Curr Pharm Des | 2026 | https://conductscience.org/library/papers/42836499 | PubMed |
| 42819747 | Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe. | Lancet Reg Health Eur | 2026 | https://conductscience.org/library/papers/42819747 | PubMed |
| 42799607 | Patient characteristics to guide personalized treatment decisions and prognostication in hepatocellular carcinoma. | Hepat Oncol | 2026 | https://conductscience.org/library/papers/42799607 | PubMed |
| 42795014 | Systemic Therapy for Advanced Hepatocellular Carcinoma with Impaired Liver Function: Navigating the Evidence Gap. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42795014 | PubMed |
| 42793258 | AI-Powered Marine Drug Discovery: A Putative Dual c-Met/VEGFR2 Lead Candidate for Hepatocellular Carcinoma via Deep Learning and Multiscale Simulation. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42793258 | PubMed |
| 42769860 | From mechanisms to practice: risk management and multidisciplinary decision-making for systemic treatment-related liver injury in HBV-associated hepatocellular carcinoma. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42769860 | PubMed |
| 42707173 | The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42707173 | PubMed |
| 42697413 | Comparative Analysis of Primary and Liver Fibroblasts Reveals MET as a Potent Target in Pancreatic Cancer Metastasis. | Cell Mol Gastroenterol Hepatol | 2026 | https://conductscience.org/library/papers/42697413 | PubMed |
| 42678589 | Regorafenib as Second-Line Versus Later-Line Therapy in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study with Exploratory Analysis of Prior Immune Checkpoint Inhibitor Exposure. | Target Oncol | 2026 | https://conductscience.org/library/papers/42678589 | PubMed |
| 42676671 | Cabozantinib-associated therapy-refractory lower-leg ulcers in metastatic renal cell carcinoma. | JAAD Case Rep | 2026 | https://conductscience.org/library/papers/42676671 | PubMed |
| 42652118 | Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: From Targeted Therapy and Combination Strategies to Emerging Therapies. | Biomedicines | 2026 | https://conductscience.org/library/papers/42652118 | PubMed |
| 42645178 | 1D228 Attenuates Sorafenib Resistance in Renal Cell Carcinoma Models by Dual Targeting c-Met and AXL. | Cells | 2026 | https://conductscience.org/library/papers/42645178 | PubMed |
| 42645031 | Tumor Microenvironment-on-a-Chip: Construction and Application in Traditional Chinese Medicine Anti-Tumor Therapy. | Biosensors (Basel) | 2026 | https://conductscience.org/library/papers/42645031 | PubMed |
Genes7
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AXL | 558 | PubTator's text mining | https://conductscience.org/library/genes/558 | NCBI Gene |
| FLT1 | 2321 | PubTator's text mining | https://conductscience.org/library/genes/2321 | NCBI Gene |
| FLT4 | 2324 | PubTator's text mining | https://conductscience.org/library/genes/2324 | NCBI Gene |
| KDR | 3791 | PubTator's text mining | https://conductscience.org/library/genes/3791 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
| TXK | 7294 | PubTator's text mining | https://conductscience.org/library/genes/7294 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| REGORAFENIB | CHEMBL1946170 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1946170 | ChEMBL |
| CABOZANTINIB | CHEMBL2105717 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL2105717 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/29972759
GET https://conductscience.org/api/papers/v1/29972759/authors?page=2